Bank of America Corp DE lifted its stake in shares of Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR - Free Report) by 617.0% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 227,132 shares of the company's stock after acquiring an additional 195,454 shares during the quarter. Bank of America Corp DE owned 0.32% of Structure Therapeutics worth $10,948,000 as of its most recent filing with the Securities and Exchange Commission.

• 3 Ways to Invest in the Growing GLP-1 Weight Loss Market

Several other institutional investors and hedge funds have also made changes to their positions in GPCR. Morgan Stanley increased its position in Structure Therapeutics by 261.4% during the fourth quarter. Morgan Stanley now owns 2,087,834 shares of the company's stock worth $145,209,000 after buying an additional 1,510,093 shares during the period. Wellington Management Group LLP boosted its position in shares of Structure Therapeutics by 25.2% in the 4th quarter. Wellington Management Group LLP now owns 7,121,984 shares of the company's stock worth $495,334,000 after buying an additional 1,432,797 shares in the last quarter. Price T Rowe Associates Inc. MD raised its position in shares of Structure Therapeutics by 477.5% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,671,138 shares of the company's stock worth $116,228,000 after purchasing an additional 1,381,745 shares during the last quarter. Avoro Capital Advisors LLC lifted its position in shares of Structure Therapeutics by 21.3% in the fourth quarter. Avoro Capital Advisors LLC now owns 6,555,555 shares of the company's stock valued at $455,939,000 after acquiring an additional 1,150,000 shares in the last quarter. Finally, Capitolis Liquid Global Markets LLC purchased a new stake in shares of Structure Therapeutics during the fourth quarter worth about $61,086,000. 91.78% of the stock is owned by institutional investors and hedge funds.

Structure Therapeutics Stock Performance

Shares of NASDAQ GPCR opened at $49.09 on Monday. The business has a 50-day moving average price of $50.30 and a two-hundred day moving average price of $51.34. Structure Therapeutics Inc. Sponsored ADR has a one year low of $18.26 and a one year high of $94.90. The firm has a market capitalization of $3.42 billion, a PE ratio of -49.09 and a beta of -1.43.

• 3 Companies at the Forefront of the GLP-1 Pill Wars

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last announced its quarterly earnings results on Thursday, August 6th. The company reported ($0.49) earnings per share for the quarter, missing analysts' consensus estimates of ($0.39) by ($0.10). Research analysts anticipate that Structure Therapeutics Inc. Sponsored ADR will post -1.84 EPS for the current year.

Analyst Upgrades and Downgrades

GPCR has been the topic of a number of research analyst reports. Citigroup reissued a "market outperform" rating on shares of Structure Therapeutics in a research note on Friday, August 7th. Canaccord Genuity Group set a $111.00 price target on Structure Therapeutics in a report on Friday, August 7th. Weiss Ratings reissued a "sell (d-)" rating on shares of Structure Therapeutics in a report on Friday, July 17th. Wall Street Zen upgraded shares of Structure Therapeutics from a "strong sell" rating to a "sell" rating in a research note on Monday, August 17th. Finally, HC Wainwright decreased their price objective on shares of Structure Therapeutics from $100.00 to $70.00 and set a "buy" rating for the company in a report on Thursday, June 11th. Three investment analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $110.91.

• Can Roche Challenge Lilly and Novo in the Weight Loss Market?

View Our Latest Stock Report on Structure Therapeutics

Structure Therapeutics Company Profile

(Free Report)

Structure Therapeutics NASDAQ: GPCR is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.

Featured Articles

• Five stocks we like better than Structure Therapeutics
• VIG, VYM, and VYMI: Which Vanguard Dividend ETF Is Right for You?
• 3 Closed-End Funds to Maximize Dividend Payments
• Rocket Lab's Sell-Off Is Fading—Is It Finally Safe to Buy?
• $27 Billion in Buybacks: 3 Stocks Betting Their Strong Runs Aren’t Over

Want to see what other hedge funds are holding GPCR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Structure Therapeutics Right Now?

Before you consider Structure Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Structure Therapeutics wasn't on the list.

While Structure Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here